Cancers, Vol. 12, Pages 1746: Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding
Cancers, Vol. 12, Pages 1746: Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding
Cancers doi: 10.3390/cancers12071746
Authors:
Hassan Awada
Maria Teresa Voso
Paola Guglielmelli
Carmelo Gurnari
Over the past decade, new insights have emerged on the pathophysiology of essential thrombocythemia (ET), its clinical management, and associated thrombohemostatic disturbances. Here, we review the latest diagnostic and risk stratification modalities of ET and its therapeutics. Moreover, we discuss the clinical evidence-based benefits, deriving from major clinical trials, of using cytoreductive therapy and antiplatelet agents to lower the risk of fatal vascular events. Also, we focus on the condition of extreme thrombocytosis (>1000 × 109/L) and bleeding risk, the development and pathogenesis of acquired von Willebrand syndrome, and the clinical approach to this paradoxical scenario in ET.
Source: Cancers - Category: Cancer & Oncology Authors: Hassan Awada Maria Teresa Voso Paola Guglielmelli Carmelo Gurnari Tags: Review Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Clinical Trials | Thrombosis | von Willebrand Disease